Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
| Industry | Market Weight | YTD Return | |
|---|---|---|---|
| All Industries | 100.00% | 4.20% | |
| Drug Manufacturers - General | 35.51% | 14.59% | |
| Healthcare Plans | 12.81% | -7.00% | |
| Medical Devices | 12.21% | 0.11% | |
| Biotechnology | 11.94% | 1.40% | |
| Diagnostics & Research | 10.75% | -1.97% | |
| Medical Instruments & Supplies | 6.69% | 5.20% | |
| Medical Care Facilities | 2.91% | 11.88% | |
| Drug Manufacturers - Specialty & Generic | 2.69% | -6.30% | |
| Medical Distribution | 2.35% | 9.33% | |
| Health Information Services | 2.00% | 2.73% | |
| Pharmaceutical Retailers | 0.15% | -57.93% | |
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
|---|---|---|---|---|---|---|---|
| 932.50 | 878.70 | 12.90% | Buy | ||||
| 492.11 | 575.92 | 6.96% | Buy | ||||
| 147.05 | 171.95 | 5.44% | Buy | ||||
| 126.04 | 142.98 | 4.90% | Buy | ||||
| 168.05 | 184.08 | 4.56% | Buy | ||||
| 531.86 | 624.92 | 3.12% | Buy | ||||
| 239.79 | 271.79 | 2.73% | Buy | ||||
| 101.64 | 124.94 | 2.72% | Buy | ||||
| 315.91 | 318.72 | 2.60% | Buy | ||||
| 27.72 | 31.46 | 2.41% | Hold |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 144.95 | 39.084B | 0.09% | ||
| 264.96 | 20.601B | 0.10% | ||
| 138.86 | 7.363B | 0.45% | ||
| 94.37 | 7.126B | 0.35% | ||
| 55.18 | 5.134B | 0.40% |
Mutual Fund Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 221.30 | 47.799B | 0.30% | ||
| 93.32 | 47.799B | 0.30% | ||
| 132.54 | 20.601B | 0.10% | ||
| 95.75 | 14.902B | 0.80% | ||
| 95.45 | 14.902B | 0.80% |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
Daily – Vickers Top Insider Picks for 07/09/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Buyers & Sellers for 07/09/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Analyst Report: Grifols, S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
RatingPrice TargetAnalyst Report: Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
RatingPrice Target
